Liminal BioSciences Inc.
LMNL · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -17.6% | -43.6% | 7,933.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $4 | $4 | $3 | $4 |
| G&A Expenses | $5 | $4 | $9 | $4 |
| SG&A Expenses | $5 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | -$5 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9 | $8 | $7 | $8 |
| Operating Income | -$9 | -$7 | -$7 | -$10 |
| % Margin | -7,907.1% | -5,415.4% | -3,058.9% | -345,100% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | $3 |
| Pre-Tax Income | -$9 | -$8 | -$7 | -$4 |
| Tax Expense | $0 | $0 | -$2 | -$33 |
| Net Income | -$9 | -$8 | -$5 | $22 |
| % Margin | -8,161.6% | -5,623.5% | -1,980.1% | 730,500% |
| EPS | -108.05 | -90.4 | -56.41 | 259.04 |
| % Growth | -19.5% | -60.3% | -121.8% | – |
| EPS Diluted | -2.94 | -2.46 | -1.54 | 7 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 3 | 3 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$9 | -$7 | -$14 | -$10 |
| % Margin | -7,907.1% | -5,231.6% | -5,686.3% | -335,966.7% |